Influence of sodium selenite on glycoprotein contents in normal and N-nitrosodiethylamine initiated and phenobarbital promoted rat liver tumors.
Selenium in the form of sodium selenite is an essential micronutrient, that acts as an antioxidant/anticancer agent by its numerous macromolecules associated with them. This study emphasizes further evidence on its role as anticancer agent in experimental rats with N-nitrosodiethylamine (DEN) initiated (200 mg kg(-1) body weight) and phenobarbital (PB) promoted hepatoma. Serum, whole liver tissue (control animals, n=6), hepatoma and surrounding liver tissue samples from DEN-treated rats and rats supplemented with selenite (n=6) were collected. Total protein, albumin, globulin and albumin/globulin ratio were investigated. Hexose, hexosamine and sialic acid were also quantified. Animals treated with DEN resulted in significantly decreased levels of total protein, albumin and albumin/globulin ratio; on the other hand, globulin content was increased significantly when compared to control rats. We have also observed significant increased levels of hexose, hexosamine and sialic acid in serum, whole liver tissue (control), hepatoma and surrounding liver tissue of control and experimental animals. Supplementation of selenite (4 ppm) either before initiation, during initiation and/or during promotion stages alters the above biochemical changes significantly. Thus, supplementations of selenite in cancer bearing animals reduce the adverse changes that occur during cancer condition. However, the chemopreventive/chemotherapeutic effect of selenite is more pronounced when it was supplemented before and/or during initiation of cancer when compared to promotion stage. Our results emphasize the role of sodium selenite in cancer and strongly indicate its role as an essential micronutrient in cancer chemoprevention and therapy.
Thirunavukkarasu
C
C
Department of Medical Biochemistry, Dr. ALM Post-Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, 600113, Chennai, India. tchinnasamy@hotmail.com
Sakthisekaran
D
D
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced / Q000188:drug therapy*; D004052:Diethylnitrosamine; D006023:Glycoproteins / Q000032:analysis / Q000187:drug effects*; D006595:Hexosamines / Q000097:blood; D006601:Hexoses / Q000097:blood; D008099:Liver / Q000737:chemistry; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D019158:N-Acetylneuraminic Acid / Q000097:blood; D010634:Phenobarbital; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000032:analysis; D012712:Serum Globulins / Q000032:analysis; D018038:Sodium Selenite / Q000494:pharmacology* / Q000627:therapeutic use; D016019:Survival Analysis
D015415:Biomarkers; D001798:Blood Proteins; D006023:Glycoproteins; D006595:Hexosamines; D006601:Hexoses; D012709:Serum Albumin; D012712:Serum Globulins; D004052:Diethylnitrosamine; D019158:N-Acetylneuraminic Acid; D018038:Sodium Selenite; D010634:Phenobarbital